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Comparison of the Performance of Two Different ALK 
Antibody Clones (D5F3 and ALK1) in Anaplastic Large Cell 
Lymphoma (ALCL) 
Dana Martin MD, Steven Smith MD, PhD, Alden Chesney MD, Terra Lewis, 
HT(ASCP) and Raghavendra Pillappa MD 
Background
Anaplastic large cell lymphoma (ALCL) is a T-
cell lymphoma characterized by CD30 
expression and subdivided into anaplastic 
lymphoma kinase (ALK) positive and negative 
subtypes that show clinically significant 
differences in outcomes. The current standard 
for evaluating ALK status is 
immunohistochemistry using the mouse 
monoclonal anti-human CD246 (ALK1) or 
fluorescence in situ hybridization. The novel 
rabbit monoclonal anti-human CD246 (D5F3) is 
proposed as an alternative to ALK1 and FDA 
approved for diagnosis of ALK-rearranged lung 
adenocarcinoma. However, its performance has 
not been systematically tested and compared to 
ALK1 in ALCL.
Design
Twenty-seven cases of ALCL were identified 
from institutional database searches and 
retrieved. A representative slide from each case 
was stained using ALK1 and D5F3 in an 
automated slide stainer. The intensity of 
cytoplasmic staining (graded 0-3, none, faint, 
moderate and strong) and percentage of positive 
cells (0, <5, 5-50%, 50-75% and >75%) were 
evaluated for each individual clone and 
subsequently compared between the two clones.
Results
Of the twenty-seven cases, nine were previously 
diagnosed as ALK expression positive by ALK-1 
staining. Nine cases were positive for ALK 
expression by ALK1 staining (34.6%; 1 1+; 0 2+; 
8 3+), while fourteen were positive by D5F3 
staining (48.1%; 3 1+; 2 2+; 9 3+). There were 
no cases that were positive by ALK1, but not by 
D5F3, which had identified the five additional 
cases. For three of the nine cases (33.3%) 
positive by both stains, the D5F3 stained slides 
showed greater percentage of cells stained. The 
staining intensity was greater by D5F3 in one of 
nine cases, the other eight cases showed the 
same (3+) intensity by D5F3 and ALK1. FISH 
results are available in five cases (19.2%) and 
demonstrated 100% concordance with ALK 
expression by both IHC stains (four positive, one 
negative).
Conclusions
These findings support the use of D5F3 as an 
equivalent and potentially more sensitive 
alternative to ALK1 for the evaluation of ALK 
positivity in ALCL.
Figure1: Immunohistochemical staining of ALK-1 (A) and D5F3 (B) of a lymph node
fine needle biopsy at 10x magnification with 40x inserts.
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
D5F3 clone
ALK1 clone
Positive Negative
N = 27
Figure 2. Comparison of stain results.   
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Figure 4: Comparison of percentage of positive lesional cells. 
Figure 3: Comparison of cytoplasmic stain intensity on a 0-3 scale.  
